The present disclosure relates to systems and methods for percutaneous implantation of a heart valve prosthesis. More particularly, the disclosure relates to systems and methods for deploying a transcatheter implantation of a stented prosthetic heart valve at a desired implantation site.
Diseased or otherwise deficient heart valves can be repaired or replaced with an implanted prosthetic heart valve. Conventionally, heart valve replacement surgery is an open-heart procedure conducted under general anesthesia, during which the heart is stopped and blood flow is controlled by a heart-lung bypass machine. Traditional open-heart surgery inflicts significant patient trauma and discomfort. Open-heart surgery also exposes the patient to a number of potential risks. These risks include infection, stroke, renal failure, and adverse effects associated with the use of the heart-lung bypass machine.
Due to the drawbacks of open-heart surgical procedures, there has been an increased interest in minimally invasive and percutaneous replacement of cardiac valves. With these percutaneous transcatheter (or transluminal) techniques, a valve prosthesis is compacted for delivery in a catheter and then advanced, for example, through an opening in the femoral artery and through the descending aorta to the heart. The valve prosthesis is then deployed in the annulus of the valve to be repaired (e.g., the aortic valve annulus). Although transcatheter techniques have attained widespread acceptance with respect to the delivery of conventional stents to restore vessel patency, only mixed results have been realized with percutaneous delivery of a relatively more complex prosthetic heart valve.
Various types and configurations of prosthetic heart valves are available for percutaneous valve procedures and continue to be refined. The actual shape and configuration of any particular prosthetic heart valve is dependent to some extent upon the native shape and size of the valve being repaired (i.e., mitral valve, tricuspid valve, aortic valve, or pulmonary valve). In general, prosthetic heart valve designs attempt to replicate the functions of the valve being replaced and thus will include valve leaflet-like structures. With a bioprostheses construction, the replacement valve may include a valved vein segment that is mounted in some manner within an expandable stent frame to make a valved stent (or “stented prosthetic heart valve”). For many percutaneous delivery and implantation systems, the stent frame of the valved stent is made of a self-expanding material and construction. With these systems, the valved stent is crimped down to a desired size and held in that compressed arrangement within an outer sheath, for example. Retracting the sheath from the valved stent allows the stent to self-expand to a larger diameter, such as when the valved stent is in a desired position within a patient. In other percutaneous implantation systems, the valved stent can be initially provided in an expanded or uncrimped condition, then crimped or compressed on a balloon portion of catheter until it is as close to the diameter of the catheter as possible. Once delivered to the implantation site, the balloon in inflated to deploy the prosthesis. With either of these types of percutaneous stent delivery systems, conventional sewing of the prosthetic heart valve to the patient's native tissue is typically not necessary.
In an attempt to optimize implantation, the stented prosthetic heart valve is accurately located relative to the native annulus immediately prior to full deployment from the catheter. Successful implantation can depend on the prosthetic heart valve being intimately lodge and sealed against the native annulus. If the prosthesis is incorrectly positioned relative to the native annulus, the deployed device can leak and dislodge from the native valve implantation site. As a point of reference, this same concern does not arise in the context of other vascular stents; with these procedures. If the stent is incorrectly deployed, another stent relatively easily can be redeployed in the correct location. If a stented prosthetic heart valve is cantered or moved during retraction of the delivery device, a clinician may have to recapture the heart valve and preposition it or install a new heart valve.
This summary introduces a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key or essential features of the claimed subject matter, and it is not intended to limit the scope of the claimed subject matter.
In one aspect, the disclosure is directed to a device for percutaneously deploying a stented prosthetic heart valve. The device includes a distal portion, a spacing collar, and an outer collar. The distal portion provides a coupling structure configured to selectively engage the stented prosthetic heart valve. The spacing collar is located proximal to the distal portion. The spacing collar is transitionable from a loaded state to an activated state. The spacing collar in the loaded state has a radial dimension less than the spacing collar in the activated state. The outer collar is configured to be movable relative to the distal portion and the spacing collar. The outer collar is slidably disposed over the spacing collar to provide the loaded state and is slidably retracted from the spacing collar when in the activated state.
In another aspect, the disclosure is directed to a delivery system for percutaneously deploying a stented prosthetic heart valve. The delivery system includes an inner shaft assembly extending along an axis of the delivery system. The inner shaft assembly contains a distal portion that provides a coupling structure configured to selectively engage the stented prosthetic heart valve. The delivery system also includes a spacing collar disposed on the axis of the delivery system and proximal to the distal portion. The spacing collar includes circumferentially spaced fingers having a first end coupled to the spacing collar and a second end yieldably urged away from the spacing collar in a radial direction. The fingers are transitionable from a first state in which the second end of the fingers are urged toward the spacing collar to a second state in which the second end of the fingers are expanded away from the spacing collar. Still further, the delivery system includes an outer collar disposed about the axis of the delivery system and slidably disposed over the distal portion including the coupling structure engaged with the stented prosthetic heart valve and the spacing collar including the plurality of fingers. The delivery system includes a loaded configuration where the outer collar is disposed over the spacing collar and the fingers are in the first state. The delivery system also includes an activated configuration where the outer collar is distally retracted from the spacing collar and the fingers are in the second state.
In another aspect, the disclosure is directed to a method of deploying a stented prosthetic heart valve to an implantation site having a vessel wall. For example, the stented prosthetic heart valve is disengaged from a delivery system at a delivery location. A spacing mechanism is activated after the stented prosthetic heart valve is disengaged to space at least a portion of the delivery system away from the vessel wall. The activated delivery system is retracted from the stented prosthetic heart valve.
The accompanying drawings are included to provide a further understanding of embodiments and are incorporated in and constitute a part of this specification. The drawings illustrate embodiments and together with the description serve to explain principles of embodiments. Other embodiments and many of the intended advantages of embodiments will be readily appreciated as they become better understood by reference to the following detailed description. The elements of the drawings are not necessarily to scale relative to each other. Like reference numerals designate corresponding similar parts.
In the following Detailed Description, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration specific embodiments in which the disclosure may be practiced. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope of the present disclosure. The following detailed description, therefore, is not to be taken in a limiting sense, and the scope of the present disclosure is defined by the appended claims. It is also to be understood that the features of the various exemplary embodiments described herein may be combined with each other, unless specifically noted otherwise.
The prosthetic heart valve as used in accordance with the various systems, devices, and methods of the present disclosure may include a wide variety of different configurations, such as a bioprosthetic heart valve having tissue leaflets or a synthetic heart valve having a polymeric, metallic, or tissue-engineered leaflets, and can be specifically configured for replacing any heart valve. Thus, the prosthetic heart valve useful with the systems, devices, and methods of the present disclosure can be generally used for replacement of a native aortic, mitral, pulmonic, or tricuspid valves, for use as a venous valve, or to replace a failed bioprosthesis, such as in the area of an aortic valve or mitral valve, for example.
In general terms, the prosthetic heart valves of the present disclosure include a stent or stent frame maintaining a valve structure (tissue or synthetic), with the stent having a normal, expanded arrangement and collapsible to a compressed arrangement for loading within the delivery system. The stent is normally constructed to self-deploy or self-expand when released from the delivery system. For example, the stented prosthetic heart valve useful with the present disclosure can be a prosthetic valve sold under the trade designation CoreValve® available from Medtronic CoreValve, LLC. Other non-limiting examples of transcatheter heart valve prostheses useful with systems and methods of the present disclosure are described in U.S. Publication Nos. 2006/0265056; 2007/0239266; and 2007/0239269, the teachings of each which are incorporated herein by reference. The stents or stent frames are support structures that comprise a number of struts or wire portions arranged relative to each other to provide a desired compressibility and strength to the prosthetic heart valve. In general terms, the stents or stent frames of the present disclosure are generally tubular support structures having an internal area in which valve structure leaflets will be secured. The leaflets can be formed from a verity of materials, such as autologous tissue, xenograph material, or synthetics as are known in the art. The leaflets may be provided as a homogenous, biological valve structure, such as porcine, bovine, or equine valves. Alternatively, the leaflets can be provided independent of one another (e.g., bovine or equine paracardial leaflets) and subsequently assembled to the support structure of the stent frame. In another alternative, the stent frame and leaflets can be fabricated at the same time, such as may be accomplished using high-strength nano-manufactured NiTi films produced at Advanced BioProsthetic Surfaces (ABPS), of San Antonio, Tex. for example. The stent frame support structures are generally configured to accommodate at least two (typically three) leaflets; however, replacement prosthetic heart valves of the types described herein can incorporate more than or less than three leaflets.
Some embodiments of the stent frames can be a series of wires or wire segments arranged such that they are capable of self-transitioning from a collapsed arrangement to a normal, radially expanded arrangement. In some constructions, a number of individual wires comprising the stent frame support structure can be formed of a metal or other material. These wires are arranged in such a way that the stent frame support structure allows for folding or compressing or crimping to the compressed arrangement in which the internal diameter is smaller than the internal diameter when in the natural, expanded arrangement. In the collapsed arrangement, such a stent frame support structure with attached valves can be mounted onto a delivery system. The stent frame support structures are configured so that they can be changed to their natural, expanded arrangement when desired, such as by the relative movement of one or more sheaths relative to a length of the stent frame.
The wires of these stent frame support structures in embodiments of the present disclosure can be formed from a shape memory material such as a nickel titanium alloy (e.g., Nitinol™ available from NDC of Fremont, Calif.). With this material, the support structure is self-expandable from the compressed arrangement to the natural, expanded arrangement, such as by the application of heat, energy, and the like, or by the removal of external forces (e.g., compressive forces). This stent frame support structure can also be compressed and re-expanded multiple times without damaging the structure of the stent frame. In addition, the stent frame support structure of such an embodiment may be laser-cut from a single piece of material or may be assembled from a number of different components. For these types of stent frame structures, one example of a delivery system that can be used includes a catheter with a retractable collar that covers the stent frame until it is to be deployed, at which point the collar can be retracted to allow the stent frame to self-expand. Further details of such embodiments are discussed below.
The delivery system 20 also includes or can be coupleable to a handle 42 along the axis 24 and disposed at the opposite end of the delivery system 20 from the distal portion 26. The handle 42 generally includes a housing 44 and one or more actuator mechanisms 46 (referenced generally). The housing 44 maintains the actuator mechanism(s) 46, with the handle 42 configured to selectively disengage the stented prosthetic heart valve (not shown) from the distal portion 26 with, for example, the outer collar 32 by facilitating sliding movement relative to the distal portion 26 and the spacing collar 30. The actuator mechanism(s) 46, can also be configured to selectively disengage the stented prosthetic heart valve (not shown) from the distal portion 26 with, for example, the inner shaft assembly 22.
In one example of the delivery system 20, the distal portion 26 includes a tip 50, inner member 52, spacer 54, and spindle 56. The tip 50 is disposed on the distal end of the delivery system 20, and is suited to guide the delivery system 20 through a vascular system to a desired delivery location to deploy the stented prosthetic heart valve. In the example provided, the stented prosthetic heart valve is engaged with the delivery system 20 proximal to the tip 50, around the inner member 52 and distal to the spindle 56. In one example, the stented prosthetic heart valve is coupled or anchored longitudinally to the spindle 56 with an interference fit. The spacer 54 can be used to help properly position the stented prosthetic heart valve against the spindle 56.
In some circumstances, however, the preferred location to deploy the stented prosthetic heart valve is within a region where the tip 50 is not centered within or ideally spaced-apart from a vascular wall in the location. One such circumstance can occur if the delivery system has passed through a tortuous region of vasculature, such as the aortic arch. If the tip 50 is not properly spaced from the vascular wall, a deployed stented prosthetic heart valve can be cantered against the vascular wall. Also, in cases where the tip 50 is pressed against the vascular wall, the delivery system 20 can become urged against the deployed stented prosthetic heart valve, which can make removal of the delivery system 20 difficult and/or possibly dislodge or move the stented prosthetic heart valve from its desired location.
The delivery system 20 includes the spacing collar 30, which can be used to space the tip 50 away from the vascular wall or to center the tip at the location of deployment. When the outer collar 32 is retracted to reveal the spacing collar 30, the fingers 34 are urged away from the spacing member 38, and the fingers 34 serve to separate the tip 50 from the vascular wall as illustrated in
In order to reduce the possibility for the prosthetic valve 68 to canter or for the tip 50 to unintentionally catch against the deployed prosthetic valve 68, i.e., to “hang-up” the deployed valve 68, however, the outer collar 32 is further retracted relative to the spacing collar 30 to activate the fingers 34, as illustrated in
The activated delivery system 20 is then retracted from the stented prosthetic heart valve 68, as illustrated in
Although specific embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that a variety of alternate and/or equivalent implementations may be substituted for the specific embodiments shown and described without departing from the scope of the present disclosure. This application is intended to cover any adaptations or variations of the specific embodiments discussed herein. Therefore, it is intended that this disclosure be limited only by the claims and the equivalents thereof.
This application claims priority under 35 U.S.C. §119(e)(1) to U.S. Provisional Patent Application Ser. No. 61/326,279, filed Apr. 21, 2010, entitled “Transcatheter Prosthetic Heart Valve Delivery System with Spacing Feature and Method”; the entire teachings of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
5599305 | Hermann et al. | Feb 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5906619 | Olson et al. | May 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
7101396 | Artof et al. | Sep 2006 | B2 |
7105016 | Shiu et al. | Sep 2006 | B2 |
7914575 | Guyenot et al. | Mar 2011 | B2 |
8057539 | Ghione et al. | Nov 2011 | B2 |
8414645 | Dwork et al. | Apr 2013 | B2 |
8512398 | Alkhatib | Aug 2013 | B2 |
20020091434 | Chambers | Jul 2002 | A1 |
20030199963 | Tower et al. | Oct 2003 | A1 |
20040225322 | Garrison et al. | Nov 2004 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060229561 | Huszar | Oct 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070073387 | Forster et al. | Mar 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070239266 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147160 | Ghione et al. | Jun 2008 | A1 |
20080147181 | Ghione et al. | Jun 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080262590 | Murray | Oct 2008 | A1 |
20090093876 | Nitzan et al. | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090171447 | Von Segesser et al. | Jul 2009 | A1 |
20090177275 | Case | Jul 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100121434 | Paul et al. | May 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100249915 | Zhang | Sep 2010 | A1 |
Number | Date | Country |
---|---|---|
2433700 | Jul 2007 | GB |
2006076890 | Jul 2006 | WO |
2007071436 | Jun 2007 | WO |
2008138584 | Nov 2008 | WO |
2009091509 | Jul 2009 | WO |
WO 2011025945 | Mar 2011 | WO |
Number | Date | Country | |
---|---|---|---|
20110264200 A1 | Oct 2011 | US |
Number | Date | Country | |
---|---|---|---|
61326279 | Apr 2010 | US |